257 related articles for article (PubMed ID: 1746593)
1. Innovative use of porcine factor VIII:C for immune tolerance induction.
Hay CR
Am J Med; 1991 Nov; 91(5A):27S-29S. PubMed ID: 1746593
[TBL] [Abstract][Full Text] [Related]
2. Rationale and evolution of therapy with porcine factor VIII:C.
Kernoff PB
Am J Med; 1991 Nov; 91(5A):20S-22S. PubMed ID: 1746591
[TBL] [Abstract][Full Text] [Related]
3. New protocol for immune tolerance induction in acquired hemophilia.
Nemes L; Pitlik E
Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
[TBL] [Abstract][Full Text] [Related]
4. The use of porcine factor VIII in the treatment of patients with acquired hemophilia: the United Kingdom experience.
Morrison AE; Ludlam CA
Am J Med; 1991 Nov; 91(5A):23S-26S. PubMed ID: 1746592
[TBL] [Abstract][Full Text] [Related]
5. Continuous infusion of porcine factor VIII in the management of patients with factor VIII inhibitors.
Rubinger M; Houston DS; Schwetz N; Woloschuk DM; Israels SJ; Johnston JB
Am J Hematol; 1997 Oct; 56(2):112-8. PubMed ID: 9326353
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
Reipert BM; van Helden PM; Schwarz HP; Hausl C
Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
[TBL] [Abstract][Full Text] [Related]
7. Perspectives on the use of factor IX complex concentrates in the treatment of bleeding in persons with acquired factor VIII inhibition.
Lusher JM
Am J Med; 1991 Nov; 91(5A):30S-34S. PubMed ID: 1746594
[TBL] [Abstract][Full Text] [Related]
8. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
9. Induction of immune tolerance in patients with hemophilia A and inhibitors treated with porcine VIIIC by home therapy.
Hay CR; Laurian Y; Verroust F; Preston FE; Kernoff PB
Blood; 1990 Sep; 76(5):882-6. PubMed ID: 2118396
[TBL] [Abstract][Full Text] [Related]
10. Immune tolerance therapy in patients with acquired hemophilia.
von Depka M
Hematology; 2004 Aug; 9(4):245-57. PubMed ID: 15621732
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity.
Doering CB; Gangadharan B; Dukart HZ; Spencer HT
Mol Ther; 2007 Jun; 15(6):1093-9. PubMed ID: 17387335
[TBL] [Abstract][Full Text] [Related]
12. Future approaches to factor VIII inhibitor therapy.
Hoyer LW
Am J Med; 1991 Nov; 91(5A):40S-44S. PubMed ID: 1746596
[TBL] [Abstract][Full Text] [Related]
13. Short term efficacy of recombinant porcine factor VIII in patients with factor VIII inhibitors.
Abou-Ismail MY; Vuyyala S; Prunty J; Schmaier AH; Nayak L
Haemophilia; 2020 Jul; 26(4):601-606. PubMed ID: 32338423
[TBL] [Abstract][Full Text] [Related]
14. Early eradication of factor VIII inhibitor in patients with congenital hemophilia A by immune tolerance induction with a high dose of immunoglobulin.
Mizoguchi Y; Furue A; Kagawa R; Chijimatsu I; Tomioka K; Shimomura M; Imanaka Y; Nishimura S; Saito S; Miki M; Ono A; Konishi N; Kawaguchi H; Kobayashi M
Int J Hematol; 2016 Apr; 103(4):473-7. PubMed ID: 26830966
[TBL] [Abstract][Full Text] [Related]
15. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience.
Brettler DB; Forsberg AD; Levine PH; Aledort LM; Hilgartner MW; Kasper CK; Lusher JM; McMillan C; Roberts H
Arch Intern Med; 1989 Jun; 149(6):1381-5. PubMed ID: 2499293
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives.
Ananyeva NM; Lacroix-Desmazes S; Hauser CA; Shima M; Ovanesov MV; Khrenov AV; Saenko EL
Blood Coagul Fibrinolysis; 2004 Mar; 15(2):109-24. PubMed ID: 15090997
[TBL] [Abstract][Full Text] [Related]
17. Tolerance induction in hemophilia A animal models: battling inhibitors with antigen-specific immunotherapies.
Adair P; Su Y; Scott DW
Discov Med; 2013 May; 15(84):275-82. PubMed ID: 23725600
[TBL] [Abstract][Full Text] [Related]
18. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
[TBL] [Abstract][Full Text] [Related]
19. Acquired hemophilia A: a frequently overlooked autoimmune hemorrhagic disorder.
Sakurai Y; Takeda T
J Immunol Res; 2014; 2014():320674. PubMed ID: 24741588
[TBL] [Abstract][Full Text] [Related]
20. Tolerating Factor VIII: Recent Progress.
Lacroix-Desmazes S; Voorberg J; Lillicrap D; Scott DW; Pratt KP
Front Immunol; 2019; 10():2991. PubMed ID: 31998296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
